The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawakami, Y.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawakami, Y.
Right arrow Articles by Rosenberg, S. A.

The Journal of Immunology, Vol 154, Issue 8 3961-3968, Copyright © 1995 by American Association of Immunologists

ARTICLES

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression

Y Kawakami, S Eliyahu, C Jennings, K Sakaguchi, X Kang, S Southwood, PF Robbins, A Sette, E Appella and SA Rosenberg
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Four of ten HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. Adoptive transfer of the four gp100-reactive CTL, but not the other TIL, resulted in tumor regression when infused into autologous patients along with IL-2. Tumor regression was thus correlated with the recognition of gp100 by the administered T cells (p = 0.0048). To identify the epitopes recognized by these four gp100-reactive CTL, 169 peptides containing HLA-A2.1 binding motifs were synthesized and screened for their recognition by TIL using cytotoxicity and IFN-gamma release assays. Five gp100 epitopes (two for TIL620, three for TIL660, one for TIL1143, and two for TIL1200) were recognized by CTL derived from different patients. Five of eight HLA-A2 binding melanoma epitopes (five gp100, one MART-1/Melan-A, two tyrosinase) had intermediate binding affinity to HLA-A2.1. These gp100 epitopes may be responsible for mediating tumor rejection in vivo and thus may be useful for the development of immunotherapies for patients with melanoma.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. M. Truscott, X. Wang, L. Lybarger, W. E. Biddison, C. McBerry, J. M. Martinko, J. M. Connolly, G. P. Linette, D. H. Fremont, T. H. Hansen, et al.
Human Major Histocompatibility Complex (MHC) Class I Molecules with Disulfide Traps Secure Disease-related Antigenic Peptides and Exclude Competitor Peptides
J. Biol. Chem., March 21, 2008; 283(12): 7480 - 7490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients
Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al.
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting
Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, and J. S. Weber
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Int. Immunol., October 1, 2007; 19(10): 1223 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lizee, M. A. Cantu, and P. Hwu
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5250 - 5255.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
Q.-S. Du, Y.-T. Wei, Z.-W. Pang, K.-C. Chou, and R.-B. Huang
Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction
Protein Eng. Des. Sel., September 1, 2007; 20(9): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Saha, S. K. Chatterjee, K. A. Foon, E. Celis, and M. Bhattacharya-Chatterjee
Therapy of Established Tumors in a Novel Murine Model Transgenic for Human Carcinoembryonic Antigen and HLA-A2 with a Combination of Anti-idiotype Vaccine and CTL Peptides of Carcinoembryonic Antigen
Cancer Res., March 15, 2007; 67(6): 2881 - 2892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Zhang, J. Eguchi, C. A. Kruse, G. G. Gomez, H. Fakhrai, S. Schroter, W. Ma, N. Hoa, B. Minev, C. Delgado, et al.
Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell-Based Therapeutics
Clin. Cancer Res., January 15, 2007; 13(2): 566 - 575.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Powell Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg
Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
J. Immunol., November 1, 2006; 177(9): 6527 - 6539.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Sugita, H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki
Ocular Infiltrating CD4+ T Cells from Patients with Vogt-Koyanagi-Harada Disease Recognize Human Melanocyte Antigens.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2547 - 2554.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Jackson, N. Dimopoulos, N. A. Mifsud, T. Y. Tai, Q. Chen, S. Svobodova, J. Browning, I. Luescher, L. Stockert, L. J. Old, et al.
Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1
J. Immunol., May 15, 2006; 176(10): 5908 - 5917.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Ebata, Y. Shimizu, Y. Nakayama, M. Minemura, J. Murakami, T. Kato, S. Yasumura, T. Takahara, T. Sugiyama, and S. Saito
Immature NK Cells Suppress Dendritic Cell Functions during the Development of Leukemia in a Mouse Model
J. Immunol., April 1, 2006; 176(7): 4113 - 4124.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Chapiro, S. Claverol, F. Piette, W. Ma, V. Stroobant, B. Guillaume, J.-E. Gairin, S. Morel, O. Burlet-Schiltz, B. Monsarrat, et al.
Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation
J. Immunol., January 15, 2006; 176(2): 1053 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. P. Linette, D. Zhang, F. S. Hodi, E. P. Jonasch, S. Longerich, C. P. Stowell, I. J. Webb, H. Daley, R. J. Soiffer, A. M. Cheung, et al.
Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity
Clin. Cancer Res., November 1, 2005; 11(21): 7692 - 7699.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
S. Madurga, I. Belda, X. Llora, and E. Giralt
Design of enhanced agonists through the use of a new virtual screening method: Application to peptides that bind class I major histocompatibility complex (MHC) molecules
Protein Sci., August 1, 2005; 14(8): 2069 - 2079.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. van Rhee, S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, et al.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Blood, May 15, 2005; 105(10): 3939 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mortarini, A. Scarito, D. Nonaka, M. Zanon, I. Bersani, E. Montaldi, E. Pennacchioli, R. Patuzzo, M. Santinami, and A. Anichini
Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles
Cancer Res., April 15, 2005; 65(8): 3428 - 3436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al.
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
J. Clin. Oncol., April 1, 2005; 23(10): 2346 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
C. Germeau, W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethe, E. De Plaen, T. Velu, et al.
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
J. Exp. Med., January 18, 2005; 201(2): 241 - 248.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell Jr., and S. A. Rosenberg
Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy
J. Immunol., December 15, 2004; 173(12): 7125 - 7130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura
Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice
Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Bae, J. A. Martinson, and H. G. Klingemann
Heteroclitic CD33 Peptide With Enhanced Anti-Acute Myeloid Leukemic Immunogenicity
Clin. Cancer Res., October 15, 2004; 10(20): 7043 - 7052.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Tsao, M. B. Atkins, and A. J. Sober
Management of Cutaneous Melanoma
N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al.
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma
Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu
HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells
Cancer Res., July 15, 2004; 64(14): 4980 - 4986.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Ramakrishna, J. F. Treml, L. Vitale, J. E. Connolly, T. O'Neill, P. A. Smith, C. L. Jones, L.-Z. He, J. Goldstein, P. K. Wallace, et al.
Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules
J. Immunol., March 1, 2004; 172(5): 2845 - 2852.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Benlalam, B. Linard, Y. Guilloux, A. Moreau-Aubry, L. Derre, E. Diez, B. Dreno, F. Jotereau, and N. Labarriere
Identification of Five New HLA-B*3501-Restricted Epitopes Derived from Common Melanoma-Associated Antigens, Spontaneously Recognized by Tumor-Infiltrating Lymphocytes
J. Immunol., December 1, 2003; 171(11): 6283 - 6289.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Odunsi, A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, et al.
NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer
Cancer Res., September 15, 2003; 63(18): 6076 - 6083.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Denkberg, A. Lev, L. Eisenbach, I. Benhar, and Y. Reiter
Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen
J. Immunol., September 1, 2003; 171(5): 2197 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Anichini, A. Scarito, A. Molla, G. Parmiani, and R. Mortarini
Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common {gamma}-Chain Cytokines
J. Immunol., August 15, 2003; 171(4): 2134 - 2141.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Tatsumi, C. J. Herrem, W. C. Olson, J. H. Finke, R. M. Bukowski, M. S. Kinch, E. Ranieri, and W. J. Storkus
Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma
Cancer Res., August 1, 2003; 63(15): 4481 - 4489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, S. L. Topalian, R. M. Sherry, N. P. Restifo, J. R. Wunderlich, C. A. Seipp, L. Rogers-Freezer, et al.
Recombinant Fowlpox Viruses Encoding the Anchor-modified gp100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma
Clin. Cancer Res., August 1, 2003; 9(8): 2973 - 2980.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mortarini, A. Piris, A. Maurichi, A. Molla, I. Bersani, A. Bono, C. Bartoli, M. Santinami, C. Lombardo, F. Ravagnani, et al.
Lack of Terminally Differentiated Tumor-specific CD8+ T Cells at Tumor Site in Spite of Antitumor Immunity to Self-Antigens in Human Metastatic Melanoma
Cancer Res., May 15, 2003; 63(10): 2535 - 2545.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-Y. Wang, X. Chen, M. H. Manjili, E. Repasky, R. Henderson, and J. R. Subjeck
Targeted Immunotherapy Using Reconstituted Chaperone Complexes of Heat Shock Protein 110 and Melanoma-associated Antigen gp100
Cancer Res., May 15, 2003; 63(10): 2553 - 2560.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu
Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules
J. Immunol., May 15, 2003; 170(10): 5317 - 5325.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Smith II, E. B. Walker, B. A. Fox, D. Haley, K. P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, et al.
Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses
J. Clin. Oncol., April 15, 2003; 21(8): 1562 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Pullarkat, P. P. Lee, R. Scotland, V. Rubio, S. Groshen, C. Gee, R. Lau, J. Snively, S. Sian, S. L. Woulfe, et al.
A Phase I Trial of SD-9427 (Progenipoietin) with a Multipeptide Vaccine for Resected Metastatic Melanoma
Clin. Cancer Res., April 1, 2003; 9(4): 1301 - 1312.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. J. Roszkowski, D. C. Yu, M. P. Rubinstein, M. D. McKee, D. J. Cole, and M. I. Nishimura
CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell
J. Immunol., March 1, 2003; 170(5): 2582 - 2589.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Reynolds, A. Zeleniuch-Jacquotte, R. L. Shapiro, D. F. Roses, M. N. Harris, D. Johnston, and J.-C. Bystryn
Vaccine-induced CD8+ T-cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma
Clin. Cancer Res., February 1, 2003; 9(2): 657 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. F. Robbins, M. El-Gamil, Y. F. Li, G. Zeng, M. Dudley, and S. A. Rosenberg
Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma
J. Immunol., November 15, 2002; 169(10): 6036 - 6047.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Denkberg, E. Klechevsky, and Y. Reiter
Modification of a Tumor-Derived Peptide at an HLA-A2 Anchor Residue Can Alter the Conformation of the MHC-Peptide Complex: Probing with TCR-Like Recombinant Antibodies
J. Immunol., October 15, 2002; 169(8): 4399 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Lev, H. Novak, D. Segal, and Y. Reiter
Recruitment of CTL Activity by Tumor-Specific Antibody-Mediated Targeting of Single-Chain Class I MHC-Peptide Complexes
J. Immunol., September 15, 2002; 169(6): 2988 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Wang, R. Turner, B. M. Baker, and W. E. Biddison
MHC Allele-Specific Molecular Features Determine Peptide/HLA-A2 Conformations That Are Recognized by HLA-A2-Restricted T Cell Receptors
J. Immunol., September 15, 2002; 169(6): 3146 - 3154.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Denkberg, C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity
PNAS, July 9, 2002; 99(14): 9421 - 9426.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska
Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity
J. Immunol., July 1, 2002; 169(1): 531 - 539.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Konopitzky, U. Konig, R. G. Meyer, W. Sommergruber, T. Wolfel, and T. Schweighoffer
Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2
J. Immunol., July 1, 2002; 169(1): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. L. Knutson, K. Schiffman, M. A. Cheever, and M. L. Disis
Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369-377, Results in Short-lived Peptide-specific Immunity
Clin. Cancer Res., May 1, 2002; 8(5): 1014 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, and Q. Yi
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
Blood, May 1, 2002; 99(9): 3280 - 3285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Berinstein
Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review
J. Clin. Oncol., April 15, 2002; 20(8): 2197 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Terasawa, K.-Y. Tsang, J. Gulley, P. Arlen, and J. Schlom
Identification and Characterization of a Human Agonist Cytotoxic T-Lymphocyte Epitope of Human Prostate-specific Antigen
Clin. Cancer Res., January 1, 2002; 8(1): 41 - 53.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
H. Kao, J. A. Marto, T. K. Hoffmann, J. Shabanowitz, S. D. Finkelstein, T. L. Whiteside, D. F. Hunt, and O. J. Finn
Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells
J. Exp. Med., November 5, 2001; 194(9): 1313 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Pietra, R. Mortarini, G. Parmiani, and A. Anichini
Phases of Apoptosis of Melanoma Cells, but not of Normal Melanocytes, Differently Affect Maturation of Myeloid Dendritic Cells
Cancer Res., November 1, 2001; 61(22): 8218 - 8226.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. W. Mullins, T. N. J. Bullock, T. A. Colella, V. V. Robila, and V. H. Engelhard
Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice
J. Immunol., November 1, 2001; 167(9): 4853 - 4860.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Lapointe, R. E. Royal, M. E. Reeves, I. Altomare, P. F. Robbins, and P. Hwu
Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100
J. Immunol., October 15, 2001; 167(8): 4758 - 4764.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, J. Lu, and E. Celis
Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen
Cancer Res., October 1, 2001; 61(20): 7577 - 7584.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al.
Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes
Clin. Cancer Res., October 1, 2001; 7(10): 3012 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D Jager, E Jager, and A Knuth
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer
J. Clin. Pathol., September 1, 2001; 54(9): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Dutoit, V. Rubio-Godoy, P.-Y. Dietrich, A.-L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Lienard, D. Speiser, P. Guillaume, P. Batard, et al.
Heterogeneous T-Cell Response to MAGE-A10254-262: High Avidity-specific Cytolytic T Lymphocytes Show Superior Antitumor Activity
Cancer Res., August 1, 2001; 61(15): 5850 - 5856.
[Abstract] [Full Text] [PDF]

Home page